Dr. Sloan Whitmore Rush, MD

Dr. Rush practices at Rush Eye Premium Surgical Suite LLC in Amarillo, Texas.

Dr. Rush's NPI, 1356535678, was assigned on August 29, 2007. Dr. Rush graduated from Joe R. & Teresa Lozano Long School of Medicine in 2005. Dr. Rush's Texas license number on file is N1435.

Dr. Rush's primary practice is Rush Eye Premium Surgical Suite LLC, at 7625 Fleming Ave, Amarillo, TX 79106 in Potter County. The practice phone is (806) 353-0125.

Dr. Rush's primary practice is Rush Eye Premium Surgical Suite LLC in Amarillo, Texas. Dmand AI also links Dr. Rush to 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rush practices. Vendor and product names are available with a free account.

Ophthalmology is Dr. Rush's primary specialty in the NPI Registry, under taxonomy code 207W00000X. Dr. Rush is board certified in ophthalmology by the American Board of Ophthalmology. Dmand AI has Dr. Rush's licenses on file in 3 states: Texas, Oregon and New Mexico.

Dmand AI lists age-related macular degeneration, cataract, cataract surgery with lens implant, cold sores or genital herpes, conjunctivitis, dry eye, eye infection or inflammation and eyelid inflammation among the conditions Dr. Rush treats.

CMS data shows 4,019 Medicare services from Dr. Rush across 19 procedure codes in 2024, for 972 Medicare patients. Medicare paid $445,143 for them.

CMS counts 972 Medicare patients who saw Dr. Rush in 2024. The largest group is 65 to 74, with 494 patients. 75% of them have high blood pressure, and 72% have high cholesterol. 7% are also on Medicaid. Their average risk score is 1.02, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rush's median patient age at 71, with 56% women.

In 2024, Dr. Rush wrote 881 Medicare Part D claims for 288 patients. 49% of them were for generic drugs. CMS names the drug for 787 of them, across 14 drugs with 11 or more claims each, at $61,557 in total drug cost. In 2023, CMS named 600 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 86 out of 100 for Dr. Rush for performance year 2024, reported as part of a group. Dr. Rush accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 746 procedures of cataract surgery by Dr. Rush, more than 98% of the clinicians it reports for that procedure.

Dmand AI links 67 papers to Dr. Rush, published from 2013 to 2025. 2021 was the busiest year, with 6. The most frequent topics are Visual Acuity, Tomography, Optical Coherence and Diabetic Retinopathy. Dr. Rush has published most often in Clin Ophthalmol. Dr. Rush's most frequent co-authors are Ryan Bradford Rush, MD, Antonio V. Aragon, MD and Robert M. Reinauer, MD.

Dmand AI links Dr. Rush to 2 clinical trials. Conditions studied include Astigmatism, Cataract and Lens Diseases.

CMS Open Payments shows 50 general payments to Dr. Rush from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 89% of the total. Alcon Research Ltd paid the most, $7,000.

Dr. Rush graduated from Joe R. & Teresa Lozano Long School of Medicine in 2005.

Dr. Rush is in network with 19 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 14. Check the plan with the practice before a visit.